JPWO2021181157A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021181157A5 JPWO2021181157A5 JP2022554382A JP2022554382A JPWO2021181157A5 JP WO2021181157 A5 JPWO2021181157 A5 JP WO2021181157A5 JP 2022554382 A JP2022554382 A JP 2022554382A JP 2022554382 A JP2022554382 A JP 2022554382A JP WO2021181157 A5 JPWO2021181157 A5 JP WO2021181157A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- dosage form
- medicament according
- oral administration
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 38
- 239000002775 capsule Substances 0.000 claims description 37
- 239000002552 dosage form Substances 0.000 claims description 35
- 241001678559 COVID-19 virus Species 0.000 claims description 26
- 239000003937 drug carrier Substances 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 26
- 241000711573 Coronaviridae Species 0.000 claims description 22
- 239000007909 solid dosage form Substances 0.000 claims description 20
- BXGLNXNRKRUYTH-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-(pyridin-4-ylmethyl)adamantane-1-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 BXGLNXNRKRUYTH-UHFFFAOYSA-N 0.000 claims description 13
- 208000025721 COVID-19 Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 11
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 7
- 239000007975 buffered saline Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 description 65
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- -1 WX-671 hydrogen sulfate salt Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Description
本明細書で引用される全ての特許、特許出願、及び公開された参考文献は、参照によりそれらの全体が本明細書に組み込まれる。本発明の記載された組成物及び方法の様々な修正及び変形は、本発明の範囲及び趣旨から逸脱することなく、当業者には明らかであろう。本発明は特定の実施形態に関連して説明されてきたが、本発明はそのような特定の実施形態に過度に限定されるべきではないことが理解されよう。実際、分子生物学、医学、免疫学、薬理学、ウイルス学、又は関連する分野の当業者に明らかな本発明を実施するための記載されたモードの様々な修正は、本発明の範囲内であることが意図される。
本願は下記の態様も包含する。
［態様１］
コロナウイルス疾患の治療のための方法であって、有効量のＡＢＣ２９４６４０、すなわち
［態様２］
前記コロナウイルス疾患が、ＳＡＲＳ－ＣｏＶ－２ウイルスによって引き起こされる２０１９年コロナウイルス感染症（ＣＯＶＩＤ－１９）である、態様１に記載の方法。
［態様３］
ＡＢＣ２９４６４０が塩酸塩として存在する、態様１に記載の方法。
［態様４］
薬学的に許容される担体材料を更に含み、前記ＡＢＣ２９４６４０及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様１に記載の方法。
［態様５］
薬学的に許容される担体材料を更に含み、前記ＡＢＣ２９４６４０塩酸塩及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様３に記載の方法。
［態様６］
前記剤形が、固体剤形である、態様４に記載の方法。
［態様７］
前記剤形が、固体剤形である、態様５に記載の方法。
［態様８］
前記固体剤形が、カプセルである、態様６に記載の方法。
［態様９］
前記固体剤形が、カプセルである、態様７に記載の方法。
［態様１０］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様１に記載の方法。
［態様１１］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様１に記載の方法。
［態様１２］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様３に記載の方法。
［態様１３］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様３に記載の方法。
［態様１４］
経口投与に好適な前記単位剤形が、２５０ｍｇのＡＢＣ２９４６４０塩酸塩を有するカプセルであり、投与することが、ＡＢＣ２９４６４０塩酸塩の総１日投与量を１０００ｍｇとするために、２つのカプセルを１日２回、少なくとも１０日間にわたり投与することを含む、態様５に記載の方法。
［態様１５］
ＡＢＣ２９４６４０塩酸塩及び薬学的に許容される担体材料を含み、前記薬学的に許容される担体材料が緩衝生理食塩水である、態様３に記載の方法。
［態様１６］
緩衝生理食塩水に懸濁されたＡＢＣ２９４６４０塩酸塩を含む懸濁液が形成され、投与することは、チューブを使用して胃に直接、前記懸濁液を送達することを含む、態様１５に記載の方法。
［態様１７］
有効量のＡＢＣ２９４６４０、すなわち
［態様１８］
前記コロナウイルス疾患が、ＳＡＲＳ－ＣｏＶ－２ウイルスによって引き起こされる２０１９年コロナウイルス感染症（ＣＯＶＩＤ－１９）である、態様１７に記載の方法。
［態様１９］
ＡＢＣ２９４６４０が塩酸塩として存在する、態様１７に記載の方法。
［態様２０］
薬学的に許容される担体材料を更に含み、前記ＡＢＣ２９４６４０及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様１７に記載の方法。
［態様２１］
薬学的に許容される担体材料を更に含み、前記ＡＢＣ２９４６４０塩酸塩及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様１９に記載の方法。
［態様２２］
前記剤形が、固体剤形である、態様２０に記載の方法。
［態様２３］
前記剤形が、固体剤形である、態様２１に記載の方法。
［態様２４］
前記固体剤形が、カプセルである、態様２２に記載の方法。
［態様２５］
前記固体剤形が、カプセルである、態様２３に記載の方法。
［態様２６］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様１７に記載の方法。
［態様２７］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様１９に記載の方法。
［態様２８］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様１７に記載の方法。
［態様２９］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様１９に記載の方法。
［態様３０］
経口投与に好適な前記単位剤形が、２５０ｍｇのＡＢＣ２９４６４０塩酸塩を有するカプセルであり、投与することが、ＡＢＣ２９４６４０塩酸塩の総１日投与量を１０００ｍｇとするために、２つのカプセルを１日２回、少なくとも１０日間にわたり投与することを含む、態様２１に記載の方法。
［態様３１］
ＡＢＣ２９４６４０塩酸塩及び薬学的に許容される担体材料を含み、前記薬学的に許容される担体材料が緩衝生理食塩水である、態様１９に記載の方法。
［態様３２］
緩衝生理食塩水に懸濁されたＡＢＣ２９４６４０塩酸塩を含む懸濁液が形成され、前記投与することは、チューブを使用して胃に直接、前記懸濁液を送達することを含む、態様３１に記載の方法。
［態様３３］
コロナウイルス疾患の治療のための方法であって、有効量のＷＸ－６７１すなわち
［態様３４］
前記コロナウイルス疾患が、ＳＡＲＳ－ＣｏＶ－２ウイルスによって引き起こされる２０１９年コロナウイルス感染症（ＣＯＶＩＤ－１９）である、態様３３に記載の方法。
［態様３５］
ＷＸ－６７１が、硫酸水素塩として存在する、態様３３に記載の方法。
［態様３６］
薬学的に許容される担体材料を更に含み、前記ＷＸ－６７１及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様３３に記載の方法。
［態様３７］
薬学的に許容される担体材料を更に含み、前記ＷＸ－６７１硫酸水素塩及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様３５に記載の方法。
［態様３８］
前記剤形が、固体剤形である、態様３６に記載の方法。
［態様３９］
前記剤形が、固体剤形である、態様３７に記載の方法。
［態様４０］
前記固体剤形が、カプセルである、態様３８に記載の方法。
［態様４１］
前記固体剤形が、カプセルである、態様３９に記載の方法。
［態様４２］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様３３に記載の方法。
［態様４３］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様３３に記載の方法。
［態様４４］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様３５に記載の方法。
［態様４５］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様３５に記載の方法。
［態様４６］
経口投与に好適な前記単位剤形が、２００ｍｇのＷＸ－６７１遊離塩基を有するカプセルであり、投与することが、ＷＸ－６７１の総１日投与量を２００ｍｇとするために、１つのカプセルを、１日１回、少なくとも１０日間にわたり投与することを含む、態様４０に記載の方法。
［態様４７］
経口投与に好適な前記単位剤形が、２００ｍｇのＷＸ－６７１遊離塩基を有するカプセルであり、投与することが、ＷＸ－６７１の総１日投与量を４００ｍｇとするために、２つのカプセルを、１日１回、少なくとも１０日間にわたり投与することを含む、態様４０に記載の方法。
［態様４８］
経口投与に好適な前記単位剤形が、約２３１ｍｇのＷＸ－６７１硫酸水素塩を有するカプセルであり、投与することが、ＷＸ－６７１硫酸水素塩の総１日投与量を約２３１ｍｇとするために、１つのカプセルを、１日１回、少なくとも１０日間にわたり投与することを含む、態様４１に記載の方法。
［態様４９］
経口投与に好適な前記単位剤形が、約２３１ｍｇのＷＸ－６７１硫酸水素塩を有するカプセルであり、投与することが、ＷＸ－６７１硫酸水素塩の総１日投与量を約４６３ｍｇとするために、２つのカプセルを、１日１回、少なくとも１０日間にわたり投与することを含む、態様４１に記載の方法。
［態様５０］
有効量のＷＸ－６７１、すなわち
［態様５１］
前記コロナウイルス疾患が、ＳＡＲＳ－ＣｏＶ－２ウイルスによって引き起こされる２０１９年コロナウイルス感染症（ＣＯＶＩＤ－１９）である、態様５０に記載の方法。
［態様５２］
ＷＸ－６７１が硫酸水素塩として存在する、態様５０に記載の方法。
［態様５３］
薬学的に許容される担体材料を更に含み、前記ＷＸ－６７１及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様５０に記載の方法。
［態様５４］
薬学的に許容される担体材料を更に含み、前記ＷＸ－６７１硫酸水素塩及び前記薬学的に許容される担体材料が、経口投与に好適な単位剤形にある、態様５２に記載の方法。
［態様５５］
前記単位剤形が、固体剤形である、態様５３に記載の方法。
［態様５６］
前記単位剤形が、固体剤形である、態様５４に記載の方法。
［態様５７］
前記固体剤形が、カプセルである、態様５５に記載の方法。
［態様５８］
前記固体剤形が、カプセルである、態様５６に記載の方法。
［態様５９］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様５０に記載の方法。
［態様６０］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、野生型である、態様５２に記載の方法。
［態様６１］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様５０に記載の方法。
［態様６２］
前記ＳＡＲＳ－ＣｏＶ－２ウイルスが、天然に存在するコロナウイルス変異体である、態様５２に記載の方法。
［態様６３］
経口投与に好適な前記単位剤形が、２００ｍｇ相当のＷＸ－６７１を有するカプセルであり、投与することが、ＷＸ－６７１の総１日投与量を約４００ｍｇとするために、１つのカプセルを、１日１回、少なくとも１０日間にわたり投与することを含む、態様５７に記載の方法。
［態様６４］
経口投与に好適な前記単位剤形が、２００ｍｇ相当のＷＸ－６７１を有するカプセルであり、投与することが、ＷＸ－６７１の総１日投与量を約４００ｍｇとするために、２つのカプセルを、１日１回、少なくとも１０日間にわたり投与することを含む、態様５７に記載の方法。
All patents, patent applications, and published references cited herein are incorporated by reference in their entirety. Various modifications and variations of the described compositions and methods of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it will be understood that the invention should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in molecular biology, medicine, immunology, pharmacology, virology, or related fields are within the scope of the invention. Something is intended.
The present application also includes the following embodiments.
[Aspect 1]
A method for the treatment of coronavirus disease, comprising: an effective amount of ABC294640, viz.
[Aspect 2]
The method according to aspect 1, wherein the coronavirus disease is coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.
[Aspect 3]
A method according to aspect 1, wherein ABC294640 is present as the hydrochloride salt.
[Aspect 4]
2. The method of embodiment 1, further comprising a pharmaceutically acceptable carrier material, wherein said ABC294640 and said pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 5]
4. The method of embodiment 3, further comprising a pharmaceutically acceptable carrier material, wherein said ABC294640 hydrochloride and said pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 6]
5. The method according to aspect 4, wherein the dosage form is a solid dosage form.
[Aspect 7]
6. The method according to aspect 5, wherein the dosage form is a solid dosage form.
[Aspect 8]
7. The method according to aspect 6, wherein the solid dosage form is a capsule.
[Aspect 9]
8. The method according to aspect 7, wherein the solid dosage form is a capsule.
[Aspect 10]
The method according to aspect 1, wherein the SARS-CoV-2 virus is wild type.
[Aspect 11]
A method according to aspect 1, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 12]
The method according to aspect 3, wherein the SARS-CoV-2 virus is wild type.
[Aspect 13]
4. The method of aspect 3, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 14]
Said unit dosage form suitable for oral administration is a capsule containing 250 mg of ABC294640 hydrochloride, which may be administered in two capsules twice a day to give a total daily dose of 1000 mg of ABC294640 hydrochloride. 6. The method according to aspect 5, comprising administering twice over a period of at least 10 days.
[Aspect 15]
4. The method of claim 3, comprising ABC294640 hydrochloride and a pharmaceutically acceptable carrier material, said pharmaceutically acceptable carrier material being buffered saline.
[Aspect 16]
16. A suspension comprising ABC294640 hydrochloride suspended in buffered saline is formed, and the administering comprises delivering the suspension directly to the stomach using a tube. the method of.
[Aspect 17]
An effective amount of ABC294640, i.e.
[Aspect 18]
18. The method of aspect 17, wherein the coronavirus disease is coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.
[Aspect 19]
18. The method according to aspect 17, wherein ABC294640 is present as the hydrochloride salt.
[Aspect 20]
18. The method of aspect 17, further comprising a pharmaceutically acceptable carrier material, wherein said ABC294640 and said pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 21]
20. The method of embodiment 19, further comprising a pharmaceutically acceptable carrier material, wherein said ABC294640 hydrochloride and said pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 22]
21. The method of embodiment 20, wherein the dosage form is a solid dosage form.
[Aspect 23]
22. The method according to aspect 21, wherein the dosage form is a solid dosage form.
[Aspect 24]
23. The method of embodiment 22, wherein the solid dosage form is a capsule.
[Aspect 25]
24. The method according to aspect 23, wherein the solid dosage form is a capsule.
[Aspect 26]
18. The method according to aspect 17, wherein the SARS-CoV-2 virus is wild type.
[Aspect 27]
20. The method according to aspect 19, wherein the SARS-CoV-2 virus is wild type.
[Aspect 28]
18. The method of aspect 17, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 29]
20. The method of aspect 19, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 30]
Said unit dosage form suitable for oral administration is a capsule containing 250 mg of ABC294640 hydrochloride, which may be administered in two capsules twice a day to give a total daily dose of 1000 mg of ABC294640 hydrochloride. 22. The method according to aspect 21, comprising administering twice over a period of at least 10 days.
[Aspect 31]
20. The method of claim 19, comprising ABC294640 hydrochloride and a pharmaceutically acceptable carrier material, said pharmaceutically acceptable carrier material being buffered saline.
[Aspect 32]
A suspension comprising ABC294640 hydrochloride suspended in buffered saline is formed, and the administering comprises delivering the suspension directly to the stomach using a tube. Method described.
[Aspect 33]
A method for the treatment of coronavirus disease, comprising: an effective amount of WX-671, i.e.
[Aspect 34]
34. The method of aspect 33, wherein the coronavirus disease is coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.
[Aspect 35]
A method according to aspect 33, wherein WX-671 is present as a hydrogen sulfate salt.
[Aspect 36]
34. The method of aspect 33, further comprising a pharmaceutically acceptable carrier material, wherein said WX-671 and said pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 37]
36. The method of embodiment 35, further comprising a pharmaceutically acceptable carrier material, wherein the WX-671 hydrogen sulfate salt and the pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 38]
37. The method of aspect 36, wherein the dosage form is a solid dosage form.
[Aspect 39]
38. The method of aspect 37, wherein the dosage form is a solid dosage form.
[Aspect 40]
39. The method of embodiment 38, wherein the solid dosage form is a capsule.
[Aspect 41]
40. The method of embodiment 39, wherein the solid dosage form is a capsule.
[Aspect 42]
34. The method according to aspect 33, wherein the SARS-CoV-2 virus is wild type.
[Aspect 43]
34. The method of aspect 33, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 44]
36. The method according to aspect 35, wherein the SARS-CoV-2 virus is wild type.
[Aspect 45]
36. The method of aspect 35, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 46]
Said unit dosage form suitable for oral administration is a capsule containing 200 mg of WX-671 free base, one capsule being administered to give a total daily dose of 200 mg of WX-671. 41. The method of aspect 40, comprising administering once a day for at least 10 days.
[Aspect 47]
Said unit dosage form suitable for oral administration is a capsule with 200 mg of WX-671 free base, and two capsules are administered to give a total daily dose of 400 mg of WX-671. 41. The method of aspect 40, comprising administering once a day for at least 10 days.
[Aspect 48]
The unit dosage form suitable for oral administration is a capsule having about 231 mg of WX-671 hydrogen sulfate, which can be administered to give a total daily dosage of about 231 mg of WX-671 hydrogen sulfate. , one capsule once a day for at least 10 days.
[Aspect 49]
The unit dosage form suitable for oral administration is a capsule having about 231 mg of WX-671 hydrogen sulfate, which can be administered to give a total daily dosage of about 463 mg of WX-671 hydrogen sulfate. , two capsules once a day for at least 10 days.
[Aspect 50]
An effective amount of WX-671, i.e.
[Aspect 51]
51. The method of embodiment 50, wherein the coronavirus disease is coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.
[Aspect 52]
51. The method of embodiment 50, wherein WX-671 is present as a hydrogen sulfate salt.
[Aspect 53]
51. The method of embodiment 50, further comprising a pharmaceutically acceptable carrier material, wherein said WX-671 and said pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 54]
53. The method of embodiment 52, further comprising a pharmaceutically acceptable carrier material, wherein the WX-671 hydrogen sulfate salt and the pharmaceutically acceptable carrier material are in a unit dosage form suitable for oral administration.
[Aspect 55]
54. The method of embodiment 53, wherein the unit dosage form is a solid dosage form.
[Aspect 56]
55. The method of embodiment 54, wherein the unit dosage form is a solid dosage form.
[Aspect 57]
56. The method of embodiment 55, wherein the solid dosage form is a capsule.
[Aspect 58]
57. The method of embodiment 56, wherein the solid dosage form is a capsule.
[Aspect 59]
51. The method according to aspect 50, wherein said SARS-CoV-2 virus is wild type.
[Aspect 60]
53. The method according to aspect 52, wherein the SARS-CoV-2 virus is wild type.
[Aspect 61]
51. The method of embodiment 50, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 62]
53. The method of embodiment 52, wherein the SARS-CoV-2 virus is a naturally occurring coronavirus variant.
[Aspect 63]
Said unit dosage form suitable for oral administration is a capsule containing the equivalent of 200 mg of WX-671, one capsule being administered to give a total daily dose of about 400 mg of WX-671. 58. The method of aspect 57, comprising administering once a day for at least 10 days.
[Aspect 64]
Said unit dosage form suitable for oral administration is a capsule containing the equivalent of 200 mg of WX-671, and two capsules are administered to give a total daily dose of about 400 mg of WX-671. 58. The method of aspect 57, comprising administering once a day for at least 10 days.
Claims (25)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987429P | 2020-03-10 | 2020-03-10 | |
| US62/987,429 | 2020-03-10 | ||
| US202063003601P | 2020-04-01 | 2020-04-01 | |
| US63/003,601 | 2020-04-01 | ||
| US202063034817P | 2020-06-04 | 2020-06-04 | |
| US63/034,817 | 2020-06-04 | ||
| US202063074799P | 2020-09-04 | 2020-09-04 | |
| US63/074,799 | 2020-09-04 | ||
| US202063125427P | 2020-12-15 | 2020-12-15 | |
| US63/125,427 | 2020-12-15 | ||
| PCT/IB2021/000131 WO2021181157A1 (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517920A JP2023517920A (en) | 2023-04-27 |
| JPWO2021181157A5 true JPWO2021181157A5 (en) | 2024-02-01 |
Family
ID=76548186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554382A Pending JP2023517920A (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US11052073B1 (en) |
| EP (1) | EP4117630A4 (en) |
| JP (1) | JP2023517920A (en) |
| KR (1) | KR20220151613A (en) |
| CN (2) | CN117695284A (en) |
| AU (1) | AU2021235304A1 (en) |
| BR (1) | BR112022017923A2 (en) |
| CA (1) | CA3174438A1 (en) |
| IL (1) | IL295658A (en) |
| MX (1) | MX2022011173A (en) |
| WO (1) | WO2021181157A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| US11052073B1 (en) * | 2020-03-10 | 2021-07-06 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN113398219A (en) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | Application of exocarpium citri rubrum extract for preparing medicine for inhibiting human coronavirus infection |
| EP4286851A1 (en) | 2022-06-01 | 2023-12-06 | Universität Wien | Methods and means for molecular characterization of post-viral fatigue syndrome |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1264828E (en) | 1998-07-20 | 2004-08-31 | Wilex Ag | UROQUINASE INHIBITOR |
| US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| ES2188003T3 (en) | 1998-09-18 | 2003-06-16 | Pentapharm Ag | UROQUINASE INHIBITORS. |
| JP4414652B2 (en) | 2001-03-21 | 2010-02-10 | ヴィレックス アクチェンゲゼルシャフト | Urokinase inhibitor |
| CH695999A5 (en) | 2002-02-28 | 2006-11-15 | Wilex Ag | A process for preparing 3-amidinophenylalanine derivatives. |
| AU2003253326A1 (en) | 2002-07-25 | 2004-02-16 | Wilex Ag | Method for the production of phenylalanine derivatives |
| DE10238048A1 (en) | 2002-07-25 | 2004-02-05 | Wilex Ag | Process for the preparation of phenylalanine derivatives |
| US9770349B2 (en) * | 2002-11-13 | 2017-09-26 | University Of Virginia Patent Foundation | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
| DE10323898A1 (en) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors |
| GB0420874D0 (en) | 2004-09-20 | 2004-10-20 | Swetree Technologies Ab | Modulation of flowering time and growth cessation in perennial plants |
| DE102004045720A1 (en) | 2004-09-21 | 2006-03-23 | Wilex Ag | Stable dosage form of phenylalanine derivatives |
| DE502005007959D1 (en) | 2004-10-14 | 2009-10-01 | Wilex Ag | PROCESS FOR CLEANING 3-HYDROXY-AMIDINO-PHENYLALANINE DERIVATIVES BY THE EXTRACTION AND RE-CRYSTALLIZATION OF A SALT WITH AN AROMATIC SULFONIC ACID |
| DE102004057195A1 (en) | 2004-11-26 | 2006-06-01 | Wilex Ag | Crystalline modifications of N-alpha (2,4,6-triisopropylphenylsulfonyl) -3-hydroxyamidino- (L) -phenylalanine-4-ethoxycarbonylpiperazide and / or salts thereof |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| CA2612338C (en) | 2005-06-17 | 2015-02-03 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors |
| WO2012166859A2 (en) | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| MX2017005350A (en) * | 2014-10-24 | 2017-08-15 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication. |
| CN108135168B (en) * | 2015-05-21 | 2021-07-20 | 凯莫森特里克斯股份有限公司 | CCR2 modulators |
| CN108136207A (en) * | 2015-10-06 | 2018-06-08 | 红山生物医药有限公司 | For the conjoint therapy for the treatment of cancer |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| DE102018217334A1 (en) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid base and / or active ingredient for use in the prophylaxis and / or therapy of a viral infection and / or viral infectious disease or disinfection, food / food supplements, feed / feed supplements and crop protection agents |
| US11052073B1 (en) * | 2020-03-10 | 2021-07-06 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection |
-
2021
- 2021-03-08 US US17/195,279 patent/US11052073B1/en active Active
- 2021-03-08 AU AU2021235304A patent/AU2021235304A1/en active Pending
- 2021-03-08 JP JP2022554382A patent/JP2023517920A/en active Pending
- 2021-03-08 BR BR112022017923A patent/BR112022017923A2/en unknown
- 2021-03-08 CN CN202311591091.6A patent/CN117695284A/en active Pending
- 2021-03-08 EP EP21768527.0A patent/EP4117630A4/en active Pending
- 2021-03-08 IL IL295658A patent/IL295658A/en unknown
- 2021-03-08 CA CA3174438A patent/CA3174438A1/en active Pending
- 2021-03-08 WO PCT/IB2021/000131 patent/WO2021181157A1/en unknown
- 2021-03-08 KR KR1020227029182A patent/KR20220151613A/en unknown
- 2021-03-08 MX MX2022011173A patent/MX2022011173A/en unknown
- 2021-03-08 CN CN202180022144.5A patent/CN115515560B/en active Active
- 2021-03-08 US US17/195,333 patent/US11045453B1/en active Active
- 2021-06-10 US US17/344,430 patent/US11918560B2/en active Active
- 2021-06-30 US US17/364,386 patent/US20210322390A1/en active Pending
- 2021-10-15 US US17/502,932 patent/US11364227B2/en active Active
-
2024
- 2024-01-30 US US18/426,914 patent/US20240350461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2404750C2 (en) | Composition containing base or coat for moderated release and antagonist of nmda receptor, method for introduction of such nmda antagonist to individual | |
| US6306910B1 (en) | Use of Gaba-analogues for treating insomnia | |
| JP2005515966A5 (en) | ||
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JPH08502288A (en) | Pharmaceutical composition and method for treating sensational symptoms | |
| JP2005528430A5 (en) | ||
| JP2021152060A (en) | Combination therapy using acamprosate and d-cycloserine | |
| KR20010024187A (en) | Compositions and methods for treating respiratory disorders | |
| ES2207858T3 (en) | ACTIVE PHARMACEUTICAL COMPOSITION TO REDUCE THE PRODUCTION OF PROTEIN MCP-1 ". | |
| JP2005512946A5 (en) | ||
| JPWO2021181157A5 (en) | ||
| JP2009242366A (en) | Prolonged antipyretic analgesic anti-inflammatory agent | |
| JP2006524190A5 (en) | ||
| TWI327913B (en) | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid | |
| US5580577A (en) | Method of treating the symptoms of human rhinovirus infection | |
| EP1223914A2 (en) | Orally distintegrating composition comprising mirtazapine | |
| ES2286716T3 (en) | PHARMACEUTICAL COMPOSITION OF CONTROLLED LIBERATION AND PROCESS TO PREPARE THE SAME. | |
| ES2300750T3 (en) | COMBINED USE OF A FIBRATE AND ORLISTAT FOR THE TREATMENT OF OBESITY. | |
| CN1853619A (en) | Use of agomelatin in the manufacture of a medicament for the treatment of bipolar disorders | |
| ES2356371T3 (en) | THERAPEUTIC MEDICINES TO INDUCE TOLERANCE. | |
| JP4384435B2 (en) | Sneezing suppression composition | |
| JP2009507850A5 (en) | ||
| RU2008108216A (en) | PHARMACEUTICAL DOSED FORMS AND COMPOSITIONS CONTAINING LEKOSOTAN | |
| JP2002520300A (en) | Pharmaceutical composition for treating herpes zoster comprising a GABA analog and an antiviral agent | |
| WO2022037006A1 (en) | Analgesic and antipruritic pharmaceutical composition and application method therefor |